{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T18:49:36Z","timestamp":1786992576074,"version":"build-2736575974"},"reference-count":21,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2011,8,1]],"date-time":"2011-08-01T00:00:00Z","timestamp":1312156800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2013,7,16]],"date-time":"2013-07-16T00:00:00Z","timestamp":1373932800000},"content-version":"vor","delay-in-days":715,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of Hepatology"],"published-print":{"date-parts":[[2011,8]]},"DOI":"10.1016\/j.jhep.2011.02.006","type":"journal-article","created":{"date-parts":[[2011,2,23]],"date-time":"2011-02-23T04:52:26Z","timestamp":1298436746000},"page":"268-269","source":"Crossref","is-referenced-by-count":11,"title":["Pharmacological management of hepatorenal syndrome: Lessons from non-responders"],"prefix":"10.1016","volume":"55","author":[{"given":"Pere","family":"Gin\u00e8s","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jhep.2011.02.006_b0005","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1056\/NEJMra0809139","article-title":"Renal failure in cirrhosis","volume":"361","author":"Gin\u00e8s","year":"2009","journal-title":"New Engl J Med"},{"key":"10.1016\/j.jhep.2011.02.006_b0010","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1016\/S0140-6736(58)92464-4","article-title":"Haslam Rm, Sherlock S. The use of steroidal spironolactone in the treatment of ascites","volume":"2","author":"Kerr","year":"1958","journal-title":"The Lancet"},{"key":"10.1016\/j.jhep.2011.02.006_b0015","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1016\/S0140-6736(81)91617-2","article-title":"Propranolol in prevention of recurrent gastrointestinal bleeding in cirrhotic patients","volume":"1","author":"Lebrec","year":"1981","journal-title":"The Lancet"},{"key":"10.1016\/j.jhep.2011.02.006_b0020","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1002\/hep.1840120416","article-title":"Norfloxacin prevents spontaneous bacterial peritonitis recurrence in cirrhosis: results of a double-blind, placebo-controlled trial","volume":"12","author":"Gin\u00e8s","year":"1990","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2011.02.006_b0025","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1002\/hep.23286","article-title":"Systematic review of randomized trials on vasoconstrictor drugs for hepatorenal syndrome","volume":"51","author":"Gluud","year":"2010","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2011.02.006_b0030","doi-asserted-by":"crossref","unstructured":"European Association for the Study of the Liver, Gin\u00e8s P, Angeli P, Lenz K, M\u00f8ller S, Moore K, Moreau R, et al. EASL clinical practice guidelines on the management of ascites, spontaneous bacterial peritonitis and hepatorenal syndrome in cirrhosis. J Hepatol 2010;53:397\u2013417.","DOI":"10.1016\/j.jhep.2010.05.004"},{"key":"10.1016\/j.jhep.2011.02.006_b0035","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1053\/j.gastro.2008.02.024","article-title":"Terlipressin and albumin vs albumin in patients with cirrhosis and hepatorenal syndrome: a randomized study","volume":"134","author":"Mart\u00edn-Llah\u00ed","year":"2008","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2011.02.006_b0040","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1053\/j.gastro.2008.02.014","article-title":"A randomized, prospective, double-blind, placebo-controlled trial of terlipressin for type 1 hepatorenal syndrome","volume":"134","author":"Sanyal","year":"2008","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2011.02.006_b0045","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.jhep.2003.09.019","article-title":"Effects of treatment of hepatorenal syndrome before transplantation on posttransplantation outcome. A case-control study","volume":"40","author":"Restuccia","year":"2004","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2011.02.006_b0050","first-page":"S25","article-title":"Evaluation and management of pretransplant renal insufficiency and criteria for simultaneous liver\u2013kidney transplantation","volume":"15","author":"Gonwa","year":"2009","journal-title":"Liver Transpl"},{"key":"10.1016\/j.jhep.2011.02.006_b0115","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.jhep.2010.11.020","article-title":"Predictors of Response to terlipressin and albumin in hepatorenal syndrome type-1: relationship of serum creatinine to hemodynamics","volume":"55","author":"Boyer","year":"2011","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2011.02.006_b0060","first-page":"1310","article-title":"Diagnosis, prevention and treatment of the hepatorenal syndrome in cirrhosis. A consensus workshop of the international ascites club","volume":"56","author":"Salerno","year":"2007","journal-title":"Gut"},{"key":"10.1016\/j.jhep.2011.02.006_b0065","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1002\/hep.23283","article-title":"Predictors of response to therapy with terlipressin and albumin in patients with cirrhosis and type-1 hepatorenal syndrome","volume":"51","author":"Nazar","year":"2010","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2011.02.006_b0070","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1046\/j.1440-1746.2002.02816.x","article-title":"Clinical course, predictive factors, and prognosis in patients with cirrhosis and type-1 hepatorenal syndrome treated with terlipressin: a retrospective analysis","volume":"17","author":"Colle","year":"2002","journal-title":"J Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2011.02.006_b0075","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1002\/hep.510270107","article-title":"Reversibility of hepatorenal syndrome by prolonged administration of ornipressin and plasma volume expansion","volume":"27","author":"Guevara","year":"1998","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2011.02.006_b0080","doi-asserted-by":"crossref","first-page":"1690","DOI":"10.1002\/hep.510290629","article-title":"Reversal of type-1 hepatorenal syndrome with the administration of midodrine and octreotide","volume":"29","author":"Angeli","year":"1999","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2011.02.006_b0085","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1053\/jhep.2002.34343","article-title":"Effects of noradrenaline and albumin in patients with type-1 hepatorenal syndrome: a pilot study","volume":"36","author":"Duvoux","year":"2002","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2011.02.006_b0090","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1097\/shk.0b013e318050c78d","article-title":"Continous versus bolus infusion of terlipressin in ovine endotoxemia","volume":"28","author":"Lange","year":"2007","journal-title":"Shock"},{"key":"10.1016\/j.jhep.2011.02.006_b0095","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.1007\/s00134-007-0676-1","article-title":"Continuous terlipressin infusion in patients with septic shock: less may be best, and the earlier the better?","volume":"33","author":"Morelli","year":"2007","journal-title":"Intensive Care Med"},{"key":"10.1016\/j.jhep.2011.02.006_b0100","first-page":"378A","article-title":"Terlipressin given as continuous intravenous infusion is the more suitable schedule for the treatment of type-1 hepatorenal syndrome (HRS) in patients with cirrhosis: results of a controlled clinical trial","volume":"48","author":"Angeli","year":"2008","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2011.02.006_b0105","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1016\/S0168-8278(10)60008-6","article-title":"Extracoporeal liver support by fractionated plasma separation, adsorption (PROMETHEUS) in patients with acute on chronic liver failure (Helios Study): a prospective randomized Controlled multicenter study","volume":"52","author":"Rifai","year":"2010","journal-title":"J Hepatol"}],"container-title":["Journal of Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827811001814?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827811001814?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2021,11,19]],"date-time":"2021-11-19T05:17:54Z","timestamp":1637299074000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168827811001814"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,8]]},"references-count":21,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2011,8]]}},"alternative-id":["S0168827811001814"],"URL":"https:\/\/doi.org\/10.1016\/j.jhep.2011.02.006","relation":{},"ISSN":["0168-8278"],"issn-type":[{"value":"0168-8278","type":"print"}],"subject":[],"published":{"date-parts":[[2011,8]]}}}